Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.74 |
| ▸ | BRD2 | P25440 | 9/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 8/20 | 0.55 |
| ▸ | CCL2 | P13500 | 1/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TAF1 | P21675 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15437215 | 0.92 | BRD4 (0.72) | BRD4BRD2BRD3CCL2 | |
| SCHEMBL15437456 | 0.89 | BRD4 (0.75) | BRD4BRD2BRD3CCL2TRIM24 | |
| SCHEMBL15437213 | 0.89 | BRD4 (0.68) | BRD4BRD2BRD3CCL2 | |
| SCHEMBL15437469 | 0.83 | BRD4 (0.81) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL15450326 | 0.83 | BRD4 (0.77) | BRD4BRD2BRD3CCL2 | |
| SCHEMBL13723304 | 0.81 | BRD4 (0.73) | BRD4BRD2BRD3CCL2 | |
| SCHEMBL13723705 | 0.80 | BRD4 (0.69) | BRD4BRD2BRD3CCL2 | |
| SCHEMBL13724287 | 0.79 | BRD4 (0.78) | BRD4BRD2BRD3CCL2TRIM24 | |
| SCHEMBL15450350 | 0.79 | BRD4 (0.69) | BRD4BRD2BRD3CCL2 | |
| SCHEMBL15437198 | 0.79 | BRD4 (0.69) | BRD4BRD2BRD3CCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3168213-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3168213-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3168213-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-3168213-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2699551-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2699551-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8993554-B2 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993554-B2 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993554-B2 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | BRD4, BRDT, BRD3 | BRD4 1/4885BRD2 4/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.